Prevention of endometriosis recurrence after surgical treatment

S. V. Apresyan, A. E. Markarov, Ju. E. Dobrokhotova, S. А. Khlynova, Valentina Dimitrova, S.A. Papoyan, Е. А. Маркова, O. A. Slyusareva
In: Meditsinskiy sovet = Medical Council · 2023 · pp. 12–25 · doi:10.21518/ms2023-341 · W4387878227
article OA: diamond CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Dienogest suppressive therapy after surgery for endometriosis and adenomyosis reduced pain and improved quality of life, with 48% of patients realizing reproductive function over 24 months.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

The study investigated outcomes after organ-preserving surgery in 80 reproductive-age patients with external genital endometriosis and nodular adenomyosis, comparing 65 patients receiving continuous dienogest (2 mg/day) from postoperative day 2 for 6 months versus 15 patients who declined dienogest. After surgery, pain intensity was evaluated using VAS, NRS, and B&B scales at 3 and 6 months, and quality of life was assessed with the EНР-30 questionnaire; the authors also report follow-up over 24 months. Patients treated with dienogest showed stepwise pain score reduction by 3 months and a further decrease to minimal levels by 6 months (p<0.05), alongside improved quality of life, and the paper states that 24-month outcomes included prevention of recurrences and good safety/tolerability with high compliance. The paper’s limitation is the non-randomized, small control group size (self-selection refusal of therapy), which limits causal inference. This paper is centrally about endometriosis and adenomyosis—specifically preventing recurrence and reducing postoperative pain with dienogest after surgery in patients with external genital endometriosis and nodular adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Introduction . The relevance of studying the mechanisms underlying the development of adenomyosis is determined not only by its high prevalence reaching 40% among reproductive aged women, but also by its association with unexplained infertility (60%), as well as woman’s quality of life impairment. Aim . To enhance efficiency of therapy after surgical treatment of endometriosis and minimize the risk of disease recurrence. Materials and methods . In a cohort prospective comparative study conducted on the basis of the gynecological department of the Inozemtsev City Clinical Hospital, 80 patients of reproductive age who underwent organ-preserving treatment for external genital endometriosis and nodular adenomyosis were included. Dienogest (Zafrilla) was prescribed to 65 patients at a dose of 2 mg/day (1 tablet) from day 2 after surgical treatment continuously for 6 months, taking into account contraindications to its use, 15 patients refused to take the drug in the postoperative period, and made up the control group. Results . The results of the study showed that after surgical treatment of external genital endometriosis and the nodular form of adenomyosis and the appointment of suppressive therapy with Zafrilla, after 3 months, the intensity of the pain syndrome was transformed according to the VAS, NRS, B&B scales by one step, and after 6 months it decreased to a slight (p < 0.05), which contributed to the improvement of the quality of life of patients based on the EHP-30 questionnaire. The long-term results of the study allow us to recommend the drug Zafrilla, with high compliance, good tolerance, a favorable safety profile, in order to reduce pain, the intensity of menstrual flow, and prevent recurrence of the disease based on 24 months of observation. Conclusion . An integrated approach to the treatment of external genital endometriosis and nodular adenomyosis, including surgical treatment and suppressive therapy with Zafrilla, made it possible to realize reproductive function in 48% of patients. Taking dienogest for 24 weeks provided effective relief of pain, alleviated the symptoms of the disease, as well as improved the quality of life and realized reproductive plans.

My notes (saved in your browser only)

Outcome instruments

EHP-30 VAS-pain NRS-pain

Condition tags

endometriosisadenomyosisinfertility

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (53)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK